Drugs / PR51
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00551915 | May 2001 → Jan 2003 | — | Merck Sharp & Dohme LLC | Completed | Mixed |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PR51 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00551915 ↗ |
| Modality | Vaccine | “vaccine formulation containing 3 mcg of PRP-OMPC and 10 mcg of HBsAg” NCT00551915 ↗ |
| Route | Intramuscular | “Participants were vaccinated with 0.5 ml of PR51 (3,10) formulation via intramuscular injection” NCT00551915 ↗ |